• Voluntis, AstraZeneca to Test Mobile App Supporting Patients with Platinum-Resistant Ovarian Cancer
  • Upcoming Phase 2 Trial to Evaluate DPX-Survivac with Keytruda in Ovarian, Other Solid Tumors
  • Two-pronged Antibody Can Help Efficiently Destroy Ovarian Cancer Cells, Researchers Find
  • Celsion Doses First Ovarian Cancer Patient in Phase 1/2 Trial of GEN-1
  • IMV’s Ovarian Cancer Trial Testing Triple Combo Therapy Doses First Patient
  • Ovarian Cancer Cells Retain Iron to Fuel Growth, Research Suggests
  • Sorafenib plus Hycamtin Combo Prolongs Survival in Platinum-resistant Ovarian Cancer, Phase 2 Trial Shows
  • Algorithm Predicts Response to Measles Virus Therapy in Ovarian, Other Cancers, Study Shows
  • FDA OKs Phase 2 Trial Evaluating 2X-121 in Advanced Ovarian Cancer Patients
  • Aravive Biologics’ Therapy Earns FDA’s Fast Track Designation to Treat Advanced Ovarian Cancer
  • Silencing GULP1 Gene Aids Ovarian Cancer Progression, Study Suggests
  • Phase 2 Trial Shows Dalantercept Has Limited Effectiveness in Ovarian Cancer Patients